图片来源： a16z Z Highlights 2025 年初，一份匿名文件在网上流传。里面列出了 100 多个此前未知的 Microsoft Access 和 365 漏洞，内容包括技术验证、堆栈追踪、利用链分析，细致 详尽。 信息源来自一个自称 "Unpatched AI" 的工具，没有团队、没有公司，只有这些发现。 一开始，安全圈对这件事有些迷惑。漏洞都是真实存在的，分析报告极其专业，显然用了自动化工具。但从覆盖面、利用链的复杂度和准确率来看，这远 远超出了普通扫描器或脚本的水平。 公开信息显示，这背后是一个自主的、由大语言模型（ LLM ）驱动的漏洞研究管道，融合了现代模糊测试、符号执 行和生成式 AI 来完成报告撰写。虽然背后团队身份依然未知，但这种工具的潜力已经显现 —— 它们有可能彻底改变网络攻防格局。 这也带来了一个令人不安的问题： 当最厉害的 " 渗透测试员 " 不再是人类，会发生什么？ 现在，这已经不是假设。自主系统正在进军攻防安全领域，有些场合甚至已超越了人类研究员。它们开始在公开漏洞悬赏排行榜上崭露头角，可以大规模 自动挖掘漏洞，无需人工指导就能规划复杂的攻击路径。 这标志着攻防安全领 ...

Data shows excretion of codeine in fingerprint sweat INBS’ System is viable option for non-invasive diagnostic testing NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that it will present its Pharmacokinetic (“PK”) study data at the Association for Diagnostics and Laboratory Medicine (“ADLM”) 2025 Clinical Lab Expo, tak ...

LIVERMORE, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) will report financial results for its 2025 fiscal second quarter on Wednesday, July 30th, 2025, at 1:25 p.m. Pacific Time. The public is invited to listen to a live webcast of FormFactor's conference call on the Investors section of the company's web site at www.formfactor.com. To Listen via Telephone: Preregistration is required. Please preregister by clicking here. Upon registering, you will be emailed a dial-in number, ...

As more companies are selling nutrition and health-testing services, a WSJ reporter decided to try one. Things got weird. https://t.co/mTIz4YvZXh ...

Waymo’s first self-driving taxis arrived in New York City this week to begin collecting data with a human behind the wheel as the company seeks a permit for autonomous testing https://t.co/EBdBNy0QKi ...

[Music] When I was scrolling through YouTube one day, I stumbled upon a video that horrified me. It was a rabbit wearing makeup. It was wearing lipstick.Hi, my name is Kira Wong Chu from Ya Guangjo School. I have a deep love for animals and today I hope to inspire all of you to stop the cruelty of animal testing. I was horrified to learn that humans test products on animals like creams, cosmetics, makeup, and medication on innocent animals such as mice and rabbits.The injuries they get are skin irritation, ...

Advances in detecting cancer recurrence uh earlier and uh more accurately are transforming how the disease is treated and monitored. One of the companies on the leading edge is Nera. Joining us now, Nera CEO Steve Chapman.The company is celebrating 10 years since going public on the NASDAQ and you got a a real market cap uh at this point and some really good um not only peer-reviewed research, you've got a product. Uh I think you were cash did you have a profit or at least cash flow positive at this point. ...

Financial Performance & Guidance - Q1 revenue reached $30.1 million, exceeding consensus estimates[10] - Q2 revenue guidance is projected between $40.0 million and $42.0 million, with net income of approximately $0.02 per share[11] - Full-year revenue guidance is set at $170 million to $175 million, with net income between $0.22 and $0.24 per share[11] - The company held $183.6 million in cash and investments as of March 31, 2019[11] Market Growth - Microbiome market revenue increased by 83% compared to Q1 2018[11] - Genomics sales in Asia increased by 231% compared to Q1 2018[11] - Domestic HCV revenues increased by 12% compared to Q1 2018[11] - International HCV sales increased by 119% compared to Q1 2018, primarily in Asia and Eastern Europe[11] Strategic Focus - The company is an industry leader in DNA/RNA sample self-collection, stabilization, and preparation products, as well as rapid point-of-care infectious disease testing[8] - The company is expanding further in established markets with strong demand for OraQuick HIV Self Test and OraQuick HCV test[8]

COVID-19 Related Opportunities - OraSure has multiple near-term COVID-19 opportunities, including two oral fluid self-collection devices for molecular testing that have received EUAs and CE-IVD marks[3] - The company is pursuing EUA for a lab-based oral fluid antibody test and developing a rapid antigen self-test[3] - OraSure is expanding manufacturing capacity to meet anticipated demand for COVID-19 tests, aiming to reach 55 million total tests per year by Q1 2021 and 70 million total tests per year by Q3 2021[28] - The company aims to increase total capacity for all molecular collection kits to 75 million units per year by Q2 2021 and 80 million kits per year by Q3 2021[29] - OraSure is also expanding capacity for Sars-Cov-2 Oral Fluid Antibody Tests from 10 million units per year to 20 million tests per year by Q4 2021[29] HIV Self-Testing - 21% of the 38 million people with HIV do not know their status, highlighting the need for accessible testing[32] - OraSure is the international HIV self-test market share leader with oral fluid self-collection and in-home results[33] - The Plan for America continues with $267 million in FY 2020 funding and a meaningful increase proposed for FY 2021 to end the HIV epidemic[35] Other Growth Drivers - Market leading microbiome products and services offer tremendous growth potential[3] - The company has $263.7 million in cash on the balance sheet with no debt, supporting ongoing business development activities[3] - Multiple research reports project mid-teens growth for the microbiome market from 2019-2024[39]

Investment Highlights - OraSure Technologies (OTI) is positioned to return to growth in its core business in 2025[5] - OTI has a differentiated product pipeline aligned with long-term healthcare trends, with potential product milestones expected to accelerate growth in 2025 and beyond[5] - OTI has an opportunity for significant operating margin leverage as volumes grow[5] - As of Q3 2024, OTI has $279 million of cash and no debt[5, 37] Strategic Transformation - OTI is focused on strengthening its foundation, elevating core growth, and accelerating profitable growth[7, 42] - OTI aims to improve access, quality, and value of healthcare with innovation in effortless tests and sample management solutions[9] - OTI is expanding its diagnostics portfolio with new tests and next-generation platform expansion, prioritizing instrument-free tests[12, 13] - OTI's acquisition of Sherlock Biosciences strengthens and broadens its diagnostic portfolio with molecular testing capabilities[19] - OTI anticipates submitting Sherlock's disposable self-test for CT/NG to the FDA by the end of 2025, targeting a $1.5 billion and growing market[22] Financial Performance - OTI is targeting a path to 50% adjusted gross margin[40] - The company's non-GAAP gross margin was 40% in FY23 and an estimated 40% in FY24[38] - Core revenue was $143 million in FY23 and an estimated $138 million in FY24, while COVID-19 revenue was $115 million in FY23 and an estimated $45 million in FY24[38]